Elsevier

Psychosomatics

Volume 44, Issue 2, March–April 2003, Pages 120-125
Psychosomatics

A Prospective Trial of Sustained-Release Bupropion for Depression in HIV-Seropositive and AIDS Patients

https://doi.org/10.1176/appi.psy.44.2.120Get rights and content

To date, the authors know of no prospective studies of sustained-release bupropion in depressed HIV-seropositive patients. The purpose of this study was to evaluate the efficacy and tolerability of sustained-release bupropion in 20 depressed HIV-positive adult outpatients. Twenty outpatients with HIV spectrum illness, a DSM-IV-diagnosed major depressive disorder confirmed with the Structured Clinical Interview for DSM-IV, and Mini-Mental State Examination scores >20 were recruited into a 6-week, open-label, flexible-dose study of sustained-release bupropion (100–300 mg/day). Twelve patients (60%) responded to sustained-release bupropion at a mean dose of 265 mg/day. Five patients (25%) discontinued study participation secondary to adverse events. Preliminary findings suggest that sustained-release bupropion is effective for the treatment of depression in HIV-positive patients, regardless of HIV clinical staging. Furthermore, it appears to be well tolerated in patients with AIDS-related medical conditions.

Cited by (0)

Presented in part at the 154th annual meeting of the American Psychiatric Association, New Orleans, May 5–10, 2001.

View Abstract